Page 5 - Johnson & Johnson

J&J's vaccine implementation study in South Africa gets regulator nod

South Africa has yet to launch its Covid-19 vaccination programme and the government has decided to go with the J&J dose

J&J says vaccine offers 100% protection against coronavirus deaths

In the more than 44,000-person study, the vaccine prevented 66 per cent of moderate to severe cases of Covid-19

Johnson & Johnson expects Covid-19 vaccine data next week: Report

The company forecast 2021 profit well above Wall Street estimates, and its shares rose 3.4% to $171.55

S&P 500 scales new high on upbeat corporate earnings; GE jumps 8%

The Dow Jones Industrial Average rose 8.5 points, or 0.03%, at the open to 30968.55

Johnson & Johnson's one shot Covid vaccine grants lasting response in trial

More than 90% of participants made immune proteins, called neutralizing antibodies, within 29 days after receiving the shot, according to the report

Delhi HC postpones hearing on pleas against anti-profiteering to Feb 15

Petitions were listed today before the division bench for hearing, but due to elevation of one of the judges, a change in the roster is expected

COVAX gains access to 2 billion doses of vaccines for 190 member economies

First deliveries are expected to begin in the first quarter of 2021 depending upon regulatory approvals and readiness of countries for delivery

J&J has applied to South Africa for registering coronavirus vaccine

The US firm's vaccine candidate is one of at least four Covid vaccines being trialled in South Africa, along with candidates being developed by Novavax, AstraZeneca and Pfizer

Nasdaq at record high; Dow, S&P 500 lifted by J&J's vaccine result hopes

(Reuters) - The S&P 500 and the Dow reversed course to rise on Tuesday, led by drugmaker Johnson & Johnson following encouraging news on its COVID-19 vaccine, while the Nasdaq hit a record high.

J&J expects data for US authorisation of Covid-19 vaccine by February

The company paused the trial in October because of a serious medical event in one participant and resumed after getting the green light from an independent safety panel.

Covid19: Airline pilots under stress, J&J vaccine trials in youths & more

On the vaccine front, Johnson & Johnson plans to start testing its experimental Covid-19 vaccine in youths aged 12 to 18 as soon as possible

J&J plans to test Covid-19 vaccine in ages 12-18, younger ages to follow

NEW YORK (Reuters) - Johnson & Johnson plans to start testing its experimental COVID-19 vaccine in youths aged 12 to 18 as soon as possible, and the company's previous experience with the same technology in a vaccine successfully used in children could give it a leg up with regulators.

Delhi High Court defers hearing in petitions against NAA to December 7

50 petitions pending in court, court asks each petitioner to submit its arguments within five pages

AstraZeneca resumes US Covid vaccine trial; J&J prepares for same next week

(Reuters) - AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday.

World Coronavirus Dispatch: China finds infection risk in frozen food packs

Brazil's weekly cases lowest in 5 months, New Zealand has first community case in three weeks, Israel eases curbs and other pandemic-related news across the globe

Race for coronavirus cure hits reality as clinic complications mount

Regulators and drugmakers have faced questions about whether political pressure was overwhelming scientific rigor ahead of the presidential election on Nov. 3

J&J to contribute up to $5 billion to potential US opioid settlement

(Reuters) - Johnson & Johnson said on Tuesday it will contribute up to $1 billion more to a potential settlement of lawsuits alleging it and other companies fueled the U.S. opioid epidemic, bringing its total payment to $5 billion.

Johnson & Johnson beats Q3 profit estimates, raises 2020 financial forecast

Johnson & Johnson boosted revenue slightly and doubled its third-quarter profit, mainly due to a $4 billion charge for litigation costs in the year-ago quarter. The health care giant blew past Wall Street expectations and raised its financial forecast for the year. Meanwhile, the New Brunswick, New Jersey-based company disclosed late Monday that it had to temporarily pause its huge, late-stage study of a potential COVID-19 vaccine due to an unexplained illness in a study participant. Such pauses are not unusual in big studies, and it's unknown whether the participant one of 60,000 planned for the global study got J&J's shot or a placebo. The world's biggest maker of health care products on Tuesday reported net income of $3.55 billion, or $1.33 per share, up 103% from $1.75 billion, or 66 cents per share, in 2019's third quarter. Excluding one-time gains and expenses, adjusted net income was $5.87 billion, or $2.20 per share, up from $5.67 billion, or or $2.12 per share, a ...

S&P 500, Dow slip on J&J vaccine worries; Apple, Amazon prop up Nasdaq

The Dow Jones Industrial Average fell 72.57 points, or 0.25 per cent, at the open

Top headlines: Wipro Q2 profit dips, GoAir pilots stop P&W engine mid-air

From Wipro reporting decline in Q2 profit year-on-year, Godrej Properties buying land in Bengaluru to J&J pausing Covid vaccine, Business Standard brings you top news of the evening